Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis
- 26 July 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 79 (1) , 25-38
Abstract
Background and Aims: Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease characterized by the infiltration of intrahepatic tissue-resident memory CD8+ T cells (TRM). Itaconate has demonstrated therapeutic potential in modulating inflammation. An unmet need for PSC is the reduction of biliary inflammation, and we hypothesized that itaconate may directly modulate pathogenic TRM. Approach and Results: The numbers of intrahepatic CD103+ TRM were evaluated by immunofluorescence in PSC (n = 32), and the serum levels of itaconate in PSC (n = 64), primary biliary cholangitis (PBC) (n = 60), autoimmune hepatitis (AIH) (n = 49), and healthy controls (n = 109) were determined by LC-MS/MS. In addition, the frequencies and immunophenotypes of intrahepatic TRM using explants from PSC (n = 5) and healthy donors (n = 6) were quantitated by flow cytometry. The immunomodulatory properties of 4-octyl itaconate (4-OI, a cell-permeable itaconate derivative) on CD103+ TRM were studied in vitro. Finally, the therapeutic potential of itaconate was studied by the administration of 4-OI and deficiency of immune-responsive gene 1 (encodes the aconitate decarboxylase producing itaconate) in murine models of PSC. Intrahepatic CD103+ TRM was significantly expanded in PSC and was positively correlated with disease severity. Serum itaconate levels decreased in PSC. Importantly, 4-OI inhibited the induction and effector functions of CD103+ TRM in vitro. Mechanistically, 4-OI blocked DNA demethylation of RUNX3 in CD8+T cells. Moreover, 4-OI reduced intrahepatic CD103+ TRM and ameliorated liver injury in murine models of PSC. Conclusions: Itaconate exerted immunomodulatory activity on CD103+ TRM in both in vitro and murine PSC models. Our study suggests that targeting pathogenic CD103+ TRM with itaconate has therapeutic potential in PSC.Keywords
This publication has 46 references indexed in Scilit:
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitisJournal of Hepatology, 2017
- Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort studyHepatology, 2016
- ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cellsJournal of Clinical Investigation, 2016
- Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of InflammationCell Metabolism, 2016
- Tissue-resident memory T cells: local specialists in immune defenceNature Reviews Immunology, 2015
- Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitisJournal of Hepatology, 2015
- Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreementPathology International, 2010
- Simplified criteria for the diagnosis of autoimmune hepatitis†Hepatology, 2008
- Runx3 Regulates Integrin αE/CD103 and CD4 Expression during Development of CD4−/CD8+ T CellsThe Journal of Immunology, 2005
- Causal Relationship between the Loss of RUNX3 Expression and Gastric CancerCell, 2002